Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) has issued an announcement.
Vistin Pharma ASA has published its Annual Report for 2025, confirming that the final audited figures show no material changes from the preliminary full-year results released in February 2026. The report is now available to investors and other stakeholders on the company’s website, providing formal confirmation of its previously communicated financial performance.
The stability between preliminary and final numbers suggests predictable financial reporting and may support investor confidence in Vistin Pharma’s transparency and internal controls. Making the full annual report publicly accessible ensures regulatory compliance and offers shareholders detailed insight into the company’s 2025 operations and financial position.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company focused on producing active pharmaceutical ingredients and finished dosage forms. The company operates in global generic medicine markets, supplying key products such as metformin and other specialty pharmaceuticals to international customers.
Average Trading Volume: 13,812
Current Market Cap: NOK997.8M
For a thorough assessment of VP4 stock, go to TipRanks’ Stock Analysis page.